Start Printed Page 14053
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.
Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 when submitting a written request. See the SUPPLEMENTARY INFORMATION section for electronic access to the summaries of safety and effectiveness.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993-0002, 301-796-6570.
End Further Info
Start Supplemental Information
In accordance with sections 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.
The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from October 1, 2013, through December 31, 2013. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.
Table 1—List of Safety and Effectiveness Summaries for Approved PMAs Made Available From October 1, 2013, Through December 31, 2013
|PMA No., Docket No.||Applicant||Trade Name||Approval Date|
|P040043/S051, FDA-2013-M-1323||W.L. Gore & Associates, Inc||GORE® TAG® Thoracic Endoprosthesis||September 10, 2013.|
|P970053/S011, FDA-2013-M-1362||Nidek Co., Ltd||Nidek EC-5000 Excimer Laser System||September 30, 2013.|
|P020050/S012, FDA-2013-M-1321||Alcon Research, Ltd||ALLEGRETTO WAVE® Eye-Q Excimer Laser System||October 2, 2013.|
|H120005, FDA-2013-M-1322||Kaneka Pharma America LLC||Kaneka Liposorber® LA-15 System||October 10, 2013.|
|P130005, FDA-2013-M-1363||Cardiovascular Systems, Inc||Diamondback 360® Coronary Orbital Arthrectomy System||October 21, 2013.|
|P110033, FDA-2013-M-1364||Allergan||JUVÉDERM® VOLUMATM XC||October 22, 2013.|
|P100009, FDA-2013-M-1365||Abbott Vascular||MitraClip Clip Delivery System (MitraClip CDS)||October 24, 2013.|
|P100026, FDA-2013-M-1488||NeuroPace, Inc||RNS® System||November 14, 2013.|
|P130006, FDA-2013-M-1605||W.L. Gore & Associates, Inc||GORE® VIABAHN® Endoprosthesis & GORE® VIABAHB® Endoprosthesis with Heparin BioActive Surface||December 5, 2013.|
II. Electronic Access
Persons with access to the Internet may obtain the documents at http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm.
End Supplemental Information
Dated: March 7, 2014.
Assistant Commissioner for Policy.
[FR Doc. 2014-05429 Filed 3-11-14; 8:45 am]
BILLING CODE 4160-01-P